Bones & muscles GHRP / ghrelin agonist
GHRP-2
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- Also known as
- Pralmorelin
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- On the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
GHRP-2 (pralmorelin) is a synthetic ghrelin-mimic peptide that prompts the pituitary to release growth hormone, sold in the wellness market for muscle, recovery, and appetite. Its only genuine validated use is as a diagnostic test of growth hormone capacity (approved in Japan), not as a treatment, and there are no controlled trials supporting the marketed wellness benefits. As of 2026 it is not FDA-approved and is banned in sport.
At a glance
- FDA status
- Non-FDA-approved peptide (also known as pralmorelin) sold in the wellness/gray market
- What it is
- Ghrelin-receptor agonist/growth hormone-releasing peptide
- Validated use
- Only as a growth hormone diagnostic stimulus (approved in Japan), not a wellness therapy
- Sport
- Prohibited by WADA at all times
- Evidence strength
- Low research
Summary
GHRP-2 is a synthetic ghrelin-mimic peptide that prompts growth hormone release. Learn how it works, its diagnostic use in Japan, and its FDA status.
What is GHRP-2?
GHRP-2, with the generic name pralmorelin, is a synthetic six-amino acid peptide that imitates ghrelin to stimulate growth hormone release. It is sold through wellness and "research peptide" channels and promoted for muscle gain, recovery, and increased appetite. Unlike most unapproved peptides, it has a narrow legitimate role: it is approved in Japan as a diagnostic agent to test the pituitary's growth hormone capacity.
How does it work?
GHRP-2 activates the growth hormone secretagogue receptor (the ghrelin receptor) on the pituitary. Activating it has three reported effects:
- It triggers a pulse of growth hormone, and growth hormone pulses raise IGF-1 downstream.
- It tends to modestly raise other hormones such as cortisol and prolactin.
- Like other ghrelin mimics, it can stimulate appetite.
The marketed muscle and recovery claims are extrapolated from this hormone effect rather than demonstrated. This describes the proposed mechanism, separate from proven outcomes.
Is it FDA-approved?
Safety note
Status: Non-FDA-approved peptide (also known as pralmorelin) sold in the wellness/gray market
Category: Wellness and performance · Primary body area: Bones & muscles
No. GHRP-2 is not approved by the FDA; its only regulatory approval is as a diagnostic agent in Japan. The table below sets out its status with each regulator.
| Regulator | Status |
|---|---|
| FDA | Not approved, with no approved product in the U.S., and not approved for performance or anti-aging |
| U.S. compounding rules | Treated as not eligible for routine 503A compounding |
| Japan | Approved as a diagnostic agent |
| WADA | Growth hormone-releasing peptides including GHRP-2 are prohibited in sport at all times under the WADA list |
What does the research show?
Editor’s note
Evidence strength: Low research
It is validated only as a short-acting growth hormone diagnostic stimulus, with no controlled human evidence supporting the marketed muscle, recovery, or anti-aging uses.
The validated human data concern diagnosis, not treatment. According to PubMed, GHRP-2 is used to probe pituitary growth hormone reserve, as in a study of the growth hormone response, which is a diagnostic application rather than a wellness-outcome trial. There are no controlled human trials showing that GHRP-2 improves muscle, fat, recovery, or aging. The marketed uses rest on its ability to raise growth hormone, not on demonstrated benefit.
Sources: a study of GHRP-2 and the growth hormone response (Teramoto et al., Growth Hormone & IGF Research, 2023, DOI: 10.1016/j.ghir.2023.101545), indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
Compare every peptide’s status in the peptide regulatory status database
More for Bones & muscles
View all bones & muscles peptides →- FDA-approved Bones & muscles
Abaloparatide
Abaloparatide is a synthetic 34-amino acid analog of parathyroid hormone-related protein (PTHrP) that activates the PTH1 receptor to stimulate new bone formation. FDA-approved in 2017 as Tymlos, it is a daily injection for postmenopausal women and men with osteoporosis at high fracture risk, and it is capped at two years of use. In the pivotal ACTIVE trial, it cut the risk of new spine fractures by about 86% versus placebo.
- FDA-approved Bones & muscles
Calcitonin-Salmon
Miacalcin (injection), nasal spray sold as a generic
Calcitonin-salmon is an FDA-approved synthetic version of a natural hormone that slows bone breakdown, used mainly for postmenopausal osteoporosis, Paget's disease of bone, and high blood calcium (hypercalcemia). It comes as an injection, sold as Miacalcin, and as a nasal spray sold as a generic. A modest effect on fractures and a small possible cancer risk with long-term use make it a second-line option today.
- Not FDA-approved Bones & muscles
Cjc-1295
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH). In two placebo-controlled trials of healthy adults aged 21 to 61 (Teichman, 2006), a single injection raised mean growth hormone 2- to 10-fold for 6 days or more. Mean IGF-1 rose 1.5- to 3-fold, but no controlled human trial shows benefit for muscle, fat loss, recovery, or anti-aging. CJC-1295 is not FDA-approved, it is not eligible for routine pharmacy compounding, and it is banned in sport.
- FDA-approved Bones & muscles
Etelcalcetide
Etelcalcetide (sold as Parsabiv) is a peptide that activates the calcium-sensing receptor to lower parathyroid hormone, used for secondary hyperparathyroidism in people on dialysis for kidney disease. Unlike parathyroid hormone replacement, it suppresses an overactive parathyroid signal, and it is given intravenously at the end of each dialysis session. It has been FDA-approved in the U.S. since 2017.
- Not FDA-approved Bones & muscles
Follistatin-344
Follistatin-344 is a form of the natural protein follistatin that blocks myostatin, a brake on muscle growth, sold as a "research chemical" in the performance market for muscle gain. The strongest human data come from gene therapy, not the injectable peptide. In a small 2017 trial, six patients with sporadic inclusion body myositis gained a median 56.0 m per year on the 6-minute walk test after follistatin gene therapy, versus a 25.8 m decline in eight matched untreated controls (p = 0.01). It is not FDA-approved and is banned in sport.
- Not FDA-approved Bones & muscles
Ghrp-6
GHRP-6 is one of the original synthetic ghrelin-mimic peptides, sold in the wellness market to raise the body's own growth hormone and stimulate appetite. Human data are limited to short studies of growth hormone release, with no controlled trials proving the marketed muscle, recovery, or anti-aging benefits. As of 2026 it is not FDA-approved and is banned in sport.